Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Leg Amputation and Continuous Sciatic Nerve Block (CAPDAF)

This study has been terminated.
(lack of patients)
Sponsor:
Information provided by:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT00427947
First received: January 26, 2007
Last updated: December 28, 2009
Last verified: December 2009

January 26, 2007
December 28, 2009
December 2006
April 2009   (final data collection date for primary outcome measure)
Total intravenous morphine consumption [ Time Frame: during the first 72 postoperative hours following leg (below knee) amputation ] [ Designated as safety issue: No ]
To compare intravenous morphine consumption during the 72 first postoperative hours following leg (below knee) amputation
Complete list of historical versions of study NCT00427947 on ClinicalTrials.gov Archive Site
  • tolerance and adverse effects (myalgia, infection, adverse effects of local anaesthetics) of the popliteal sciatic catheter, in patients with ASA physical status 2 or 3 [ Time Frame: during the 72 first postoperative hours and on the 7th postoperative day ] [ Designated as safety issue: Yes ]
  • tolerance and adverse effects of morphine during the protocol in the 2 groups of patients [ Time Frame: during the first 72 postoperative hours ] [ Designated as safety issue: Yes ]
  • incidence of stump pain and phantom limb pain, time of outbreak, intensity (VAS), characteristics (French version of the McGill Pain Questionnaire and DN4 qu [ Time Frame: 1, 3, 6 and 12 months postoperative ] [ Designated as safety issue: No ]
  • use of prosthesis [ Time Frame: 1, 3, 6 and 12 months postoperative ] [ Designated as safety issue: No ]
  • To assess tolerance and adverse effects (myalgia, infection, adverse effects of local anaesthetics) of the popliteal sciatic catheter during the 72 first postoperative hours and on the 7th postoperative day, in patients with ASA physical status 2 or 3
  • To compare tolerance and adverse effects of morphine during the protocol in the 2 groups of patients
  • To assess the long term effects of the preoperative continuous popliteal sciatic nerve block: incidence of stump pain and phantom limb pain, time of outbreak, intensity (VAS), characteristics (French version of the McGill Pain Questionnaire and DN4 qu
  • To assess the possibility for the patients to use a prosthesis
Not Provided
Not Provided
 
Leg Amputation and Continuous Sciatic Nerve Block
Continuous Popliteal Sciatic Nerve Block Interest in Postoperative Pain Management for Patients With Leg Amputation

Analgesia following leg amputation is based on morphine administration. For elderly patients of ASA physical status 2 or 3, morphine sparing is possible when perinervous block techniques are used. Phantom limb pain complicates leg amputation in 50 to 80% of cases. Prevention of these pains has been studied in various clinical trials but the interest of perinervous block technique remains to be evaluated.

The purpose of the study is to evaluate the benefit of perioperative locoregional analgesia by ropivacaine via a popliteal sciatic catheter on intravenous morphine consumption during the 72 first postoperative hours following leg (below knee) amputation The study will be randomized, double blinded, controlled clinical trial and 84 patients undergoing leg amputation (below knee) will be included Patients will be divided into 2 groups: one group of patients who will benefit perioperative locoregional analgesia by ropivacaine via a popliteal sciatic catheter and morphine for analgesia and the other one who will benefit placebo through the catheter and morphine.

The investigators will evaluate the efficacy of the continuous popliteal sciatic nerve block in postoperative analgesia after leg amputation and prove the efficacy of a perioperative analgesia by continuous popliteal sciatic nerve block to prevent phantom limb pain after leg amputation in patients of ASA physical status 2 or 3.

Introduction:

Analgesia following leg amputation is based on morphine administration. For elderly patients of ASA physical status 2 or 3, morphine sparing is possible when perinervous block techniques are used. Indeed, per operative placement of a perinervous catheter by the surgeon allows a morphine consumption decrease of about 30%. Nevertheless, the interest of a sciatic block providing analgesia in the tibial and fibular territories has still to be assessed in this indication.

Phantom limb pain complicates leg amputation in 50 to 80% of cases. Risk factors of this complication are numerous, from central or peripheral origin. Phantom limb pain postpones patients' social and professional rehabilitation, and results in an increased medical consumption. Prevention of these pains has been studied in various clinical trials, and results need confirmation. Thus, epidural analgesia alone does not decrease the long term incidence of phantom limb pain.

Objectives:

Primary : To compare intravenous morphine consumption during the 72 first postoperative hours following leg (below knee) amputation of patients randomly assigned in two groups. One group benefit from perioperative locoregional analgesia by ropivacaine via a popliteal sciatic catheter, the other group is given placebo through the catheter.

Secondary :

  • To assess tolerance and adverse effects (myalgia, infection, adverse effects of local anaesthetics) of the popliteal sciatic catheter during the 72 first postoperative hours and on the 7th postoperative day, in patients with ASA physical status 2 or 3
  • To compare tolerance and adverse effects of morphine during the protocol in the 2 groups of patients
  • To assess the long term effects of the preoperative continuous popliteal sciatic nerve block: incidence of stump pain and phantom limb pain, time of outbreak, intensity (VAS), characteristics (French version of the McGill Pain Questionnaire and DN4 questionnaire), and the analgesic consumption over a year.
  • To assess the possibility for the patients to use a prosthesis

Population:

Eighty four patients scheduled for leg amputation (below knee), randomly allocated in 2 groups of forty patients, according to the type of analgesia. Patients were enrolled in the general and vascular surgery unit, CHU (University Hospital) Pellegrin Bordeaux.

Methods:

Randomised clinical trial, with two parallel groups, with direct individual benefit, double-blinded, realised on a population of patients undergoing leg amputation, comparing different clinical parameters of postoperative pain evaluation, and outbreak of phantom limb pain according to the group of analgesia.

  • One group of patients with locoregional analgesia associated with morphine administration (assessed treatment)
  • One group of patients with morphine analgesia only (reference treatment). Patients will be followed for one year. This study will last 3 years in a general and vascular surgery unit, inclusion will be realised during 34 months by anaesthetists and surgeons, an extension of this study for one year will be done with the objective of a cohort follow-up.

Statistical analysis will be done with intention to treat.

Anticipated results:

To prove the efficacy of the continuous popliteal sciatic nerve block in postoperative analgesia after leg amputation.

To prove the efficacy of a perioperative analgesia by continuous popliteal sciatic nerve block to prevent phantom limb pain after leg amputation in patients of ASA physical status 2 or 3.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
  • Phantom Limb
  • Leg Amputation
Drug: ropivacaine/placebo
Continuous sciatic nerve bloc
  • Experimental: 1
    Continuous sciatic nerve bloc : ropivacaine infusion
    Intervention: Drug: ropivacaine/placebo
  • Placebo Comparator: 2
    Continuous sciatic nerve bloc : NaCl Infusion
    Intervention: Drug: ropivacaine/placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
6
December 2009
April 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients scheduled for leg amputation following arteritis
  • ASA score: 2-3
  • Informed consent obtained from the patient

Exclusion Criteria:

  • Patients involved in another clinical trial
  • Post-infection OR post traumatic leg amputation
  • Blood coagulation disorders
  • Local anesthetic, morphine, or paracetamol allergy
  • Local inflammatory signs
  • Pregnant or breastfeeding women
  • Patients with protective supervision
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00427947
9440-05, 2004-037
Yes
Jean-Pierre LEROY / Clinical Research and Innovation Director, University Hospital, Bordeaux
University Hospital, Bordeaux
Not Provided
Principal Investigator: Karine NOUETTE GAULAIN, Dr University Hospital, Bordeaux, France
Study Chair: Antoine BENARD, Dr university hospital, Bordeaux, France
University Hospital, Bordeaux
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP